clinical trial · NCT07443137
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
Large-cell LymphomaRapcabtagene autoleucel (YTB323)
brief summary
This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line treatment (EOT), as defined by positive measurable residual disease detected by Foresight CLARITY (PhasED-seq). Participants will initially be pre-screened for MRD status after first line treatment (1L) with chemoimmunotherapy including a CD20 monoclonal antibody and anthracycline.
started
May 1, 2026
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Mar 2, 2026
official title
Rapcabtagene Autoleucel for Eradication of Measurable Residual Disease in Large B-Cell Lymphoma (LBCL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol